Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD.

Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD.

Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD.

Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD.

Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD.

Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD.

Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD.

Anti-CLDN6 (AB1-11) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It enhances malignant potentials and drug resistance of cervical ADC and can provide a new therapeutic strategy for uterine cervical adenocarcinoma. MW :144.66 KD.

Anti-CLDN6 (AB1-11) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It enhances malignant potentials and drug resistance of cervical ADC and can provide a new therapeutic strategy for uterine cervical adenocarcinoma. MW :144.66 KD.

Anti-CLDN6 (AB1-11) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It enhances malignant potentials and drug resistance of cervical ADC and can provide a new therapeutic strategy for uterine cervical adenocarcinoma. MW :144.66 KD.

Anti-CLDN6 (AB3-7) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It has an antitumor activity and can be used in treatment of various cancers. MW :145.0 KD.

Anti-CLDN6 (AB3-7) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It has an antitumor activity and can be used in treatment of various cancers. MW :145.0 KD.

Anti-CLDN6 (AB3-7) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It has an antitumor activity and can be used in treatment of various cancers. MW :145.0 KD.

Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD.

Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD.

Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD.

Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW :146.34 KD.

Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW :146.34 KD.

Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW :146.34 KD.

Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD.

Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD.

Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD.

Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD.

Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD.

Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD.

Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD.

Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD.

Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD.

Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD.

Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD.

Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD.

Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD.

Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD.

Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD.

Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD.

Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD.

Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD.

Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD.

Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD.

Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD.

Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD.

Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD.

Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD.

Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD.

Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD.

Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD.

Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72.

Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72.

Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72.

Anti-CTSS / Cathepsin S (Fsn0503h) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma. MW :144.28 KD.